Almirall (Almirall) Net Change in Cash : $74.6 Mil (TTM As of Jun. 2023)

View and export this data going back to . Start your Free Trial

What is Almirall Net Change in Cash?

Net Change in Cash is calculated as the total of Cash Flow from Operations , Cash Flow from Investing, Cash Flow from Financing, and Effect of Exchange Rate Changes.

Almirall's Net Change in Cash for the three months ended in Jun. 2023 was $129.2 Mil. Its Net Change in Cash for the trailing twelve months (TTM) ended in Jun. 2023 was $74.6 Mil.

Almirall Net Change in Cash Historical Data

The historical data trend for Almirall's Net Change in Cash can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Almirall Net Change in Cash Chart

Almirall Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Net Change in Cash

Get a 7-Day Free Trial

34.47

58.85

47.14

43.90

151.73

Almirall Quarterly Data
	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Dec22	Mar23	Jun23	Dec23
Net Change in Cash	Get a 7-Day Free Trial															33.33	-	-54.60	129.22	-

Almirall Net Change in Cash Calculation

Almirall's Net Change in Cash for the fiscal year that ended in Dec. 2023 is calculated as

Net Change in Cash	=	Cash Flow from Operations	+	Cash Flow from Investing	+	Cash Flow from Financing	+	Effect of Exchange Rate Changes
	=	101.947	+	-133.652	+	183.43	+	0
	=	151.7

Almirall's Net Change in Cash for the quarter that ended in Jun. 2023

Net Change in Cash = Cash Flow from Operations + Cash Flow from Investing + Cash Flow from Financing + Effect of Exchange Rate Changes

= 60.572 + -137.407 + 206.053 + 0

= 129.2

Net Change in Cash for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $74.6 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Almirall Net Change in Cash Related Terms
Thank you for viewing the detailed overview of Almirall's Net Change in Cash provided by GuruFocus.com. Please click on the following links to see related term pages.

Almirall (Almirall) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Almirall SA (OTCPK:LBTSF) » Definitions » Net Change in Cash

Comparable Companies

XMAD:FAE XMAD:RJF ZTS XTER:MRK NSE:SUNPHARMA TSE:4502 LSE:HLN XTAE:TEVA XSWX:SDZ VTRS SZSE:000538 NBIX HKSE:03692 TSE:4507 NSE:DIVISLAB BOM:500124 BOM:532321 BOM:543904 TSE:4523 NSE:TORNTPHARM

Traded in Other Exchanges

0O9B:UK ALM:Spain E2Z:Germany

Address

Ronda General Mitre 151, Barcelona, ESP, 08022

Website

http://www.almirall.es

Almirall SA is a Spain-based company engaged in development, manufacture, and selling pharmaceutical products across a range of therapeutic areas. It aims to provide treatments in areas of dermatology, respiratory, gastrointestinal, central nervous systems, and other specialties. The company operates in five segments: Sales of its own network, sales of licensees, Research and developments, Sales of Therapeutic dermatological products in the U.S., and Corporate management. The medical dermatology business in the Europe is the key driver of the company's operation. Other than Europe, the company also operates in the Americas, Asia, Africa, and Oceania through subsidiaries.

Almirall (Almirall) Headlines

From GuruFocus

Almirall and MC2 Therapeutics enter a license, collaboration and commercialization agreement for European rights to Wynzora� Cream for treatment of plaque psoriasis
By PRNewswire PRNewswire • 02-17-2021

Almirall receives positive CHMP opinion for Klisyri�? (tirbanibulin), an innovative topical treatment for actinic keratosis
By PRNewswire PRNewswire • 05-21-2021

Almirall and Tyris Therapeutics enter into strategic partnership to develop next generation gene therapies
By PRNewswire PRNewswire • 01-07-2021

Dr. Jorge Gallardo Ballart announces his intention to retire from his positions of President of the Board of Directors and Board member of Almirall
By PRNewswire PRNewswire • 02-21-2022

Almirall announces Gianfranco Nazzi as new CEO
By PRNewswire PRNewswire • 02-03-2021

The Board of Directors nominates Carlos Gallardo as Vice President of the Board
By PRNewswire PRNewswire • 11-09-2020

Almirall delivers good business performance in Q1 and reiterates full year 2022 guidance
By PRNewswire PRNewswire • 05-19-2022

Almirall delivers good business performance in Q1 and reiterates full year 2022 guidance
By PRNewswire PRNewswire • 06-18-2022

Almirall's Full-Year 2021 Results : Almirall delivers high end of the 2021 upgraded guidance with solid performance from growth drivers
By PRNewswire PRNewswire • 02-21-2022

Almirall delivers good business performance in Q1 and reiterates full year 2022 guidance
By PRNewswire PRNewswire • 06-28-2022